Pharmacodynamic and pharmacokinetic basics of rivaroxaban-Reference-Cited by-同舟云学术

Pharmacodynamic and pharmacokinetic basics of rivaroxaban

Published:2011-08-16 Issue:1 Volume:26 Page:27-32
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:

Author:

Kreutz Reinhold

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1472-8206.2011.00981.x/fullpdf

Reference20 articles.

1. Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases;Turpie;Arterioscler. Thromb. Vasc. Biol.,2007

2. Rivaroxaban: a new oral factor Xa inhibitor;Perzborn;Arterioscler. Thromb. Vasc. Biol.,2010

3. Bayer Schering Pharma AG Xarelto ® summary of product characteristics 2009 http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf

4. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity;Graff;J. Clin. Pharmacol.,2007

5. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor;Perzborn;J. Thromb. Haemost.,2005

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of immediate‐release formulation with reliable absorption of rivaroxaban in various meal regimes;Clinical and Translational Science;2024-05

2. ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose;Brazilian Journal of Medical and Biological Research;2024

3. Pharmacodynamic Study of Parallel Groups Comparing the Effect of Rivaroxaban 20 Mg (Laboratorios Leti, S.A.V.) vs Rivaroxaban 20 Mg (Bayer Laboratories) on Prothrombin Time;International Journal of Clinical Medicine;2024

4. Anticoagulation in Patients with Chronic Kidney Disease;American Journal of Nephrology;2023-11-30

5. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation;Human Genomics;2023-07-07